Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Pancreas Cancer: Investigational Targeted Approaches

October 10th 2017

Clinical Research in the Treatment of Pancreas Cancer

October 10th 2017

Management of Borderline Resectable Pancreas Cancer

October 10th 2017

Neoadjuvant Therapy Recommendations in Pancreas Cancer

October 10th 2017

Role of Adjuvant Radiation Therapy in Pancreas Cancer

October 10th 2017

Adjuvant Therapy Recommendations in Pancreas Cancer

October 10th 2017

Pancreas Cancer: Incorporating Nanoliposomal Irinotecan

October 10th 2017

Palliative Care Recommendations in Pancreas Cancer

October 10th 2017

Modifying Chemotherapy Regimens in Pancreas Cancer

October 10th 2017

Sequential Therapy for Metastatic Pancreas Cancer

October 10th 2017

Precision Medicine for Pancreatic Cancer

October 10th 2017

Biological Breakthroughs in Pancreas Cancer

October 10th 2017

Precision Medicine Has Emerging Role in mCRPC

October 6th 2017

Andrew J. Armstrong, MD, discusses emerging treatments and techniques for precision medicine in metastatic castration-resistant prostate cancer.

HR+ Breast Cancer: Updated Results From MONARCH Trials

October 2nd 2017

Abemaciclib's Value in Treating HR+ Breast Cancer

October 2nd 2017

HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3

October 2nd 2017

HR+ Breast Cancer: Resistance to Primary Therapy

October 2nd 2017

Factors in Deciding Treatment for HR+ Breast Cancer

October 2nd 2017

Heterogeneity of Metastatic HR+ Breast Cancer

October 2nd 2017

Understanding Abemaciclib: A New CDK4/6 Inhibitor

October 2nd 2017